Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has recently disclosed a 5.95% ownership stake in Avadel Pharmaceuticals plc, according to a filing made under Rule 8.3 of the Irish Takeover Panel Act, 1997. The disclosure, dated February 6, 2026, details Vanguard’s holdings as of February 5, 2026.
Vanguard’s position consists of 5,799,501 ordinary shares of US$0.01 par value each. Recent trading activity includes the purchase of 9,211 shares and the sale of 96 shares, both executed at a price of $21.60 per share.
The filing confirms that Vanguard does not hold any cash-settled or stock-settled derivatives related to Avadel’s securities, such as options or agreements to buy or sell shares. Additionally, no indemnity or option arrangements, or agreements concerning voting rights or future acquisitions and disposals of Avadel securities, were reported.